Comment
Author: Admin | 2025-04-28
Doi: 10.1007/s13300-020-00816-y. Epub 2020 Apr 15. [Article] FDA Approved Drug Products: Xenical (orlistat) capsules [Link] FDA Approved Drug Products: ALLI (orlistat) oral capsules OTC [Link] FDA: Orlistat (marketed as Alli and Xenical) Information [Link] NIH StatPearls: Orlistat [Link] DailyMed: Alli (orlistat) oral capsule [Link] Product monograph: Xenical (orlistat) oral capsules [Link] Fagron MSDS: Orlistat [Link] FDA Approved Drug Products: Xenical (orlistat) capsules for oral use (Updated 11/2022) [Link] External LinksHuman Metabolome DatabaseHMDB0015215PubChem Compound3034010PubChem Substance46508309ChemSpider2298564BindingDB24567RxNav37925ChEBI94686ChEMBLCHEMBL175247ZINCZINC000008214635Therapeutic Targets DatabaseDAP000053PharmGKBPA164776864RxListRxList Drug PageDrugs.comDrugs.com Drug PagePDRhealthPDRhealth Drug PageWikipediaOrlistatFDA labelMSDSClinical TrialsClinical Trial & Rare Diseases Add-on Data PackageExplore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview packagePhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columnsUnlock 175K+ rows when you subscribe.View sample dataNot AvailableCompletedNot AvailableObesity2somestatusstop reasonjust information to hideNot AvailableCompletedNot AvailableOverweight1somestatusstop reasonjust information to hideNot AvailableCompletedBasic ScienceObesity1somestatusstop reasonjust information to hideNot AvailableCompletedPreventionObesity / Overweight1somestatusstop reasonjust information to hideNot AvailableCompletedScreeningObesity1somestatusstop reasonjust information to hideManufacturersNot AvailablePackagersA-S Medication Solutions LLCDispensing SolutionsDiversified Healthcare Services Inc.F Hoffmann La Roche Ltd.F Hoffmann-La Roche Ltd.GlaxoSmithKline Inc.Murfreesboro Pharmaceutical Nursing SupplyNucare Pharmaceuticals Inc.Physicians Total Care Inc.Southwood PharmaceuticalsDosage FormsFormRouteStrengthCapsuleOralCapsuleOral60 mg/1TabletOral27 MGTablet, chewableOral27 mgCapsuleOral60 mgCapsuleOral120.00 mgTabletOral120.000 mgTabletOral60.000 mgCapsule, coatedOral12000000 mgTabletOral120 MGCapsule, coatedOral120 mgCapsuleOral120.000 mgCapsule, coatedOral60 mgCapsuleOral60.00 mgCapsule, gelatin coatedOral120.00 mgCapsuleOralPowderNot applicable1 kg/1kgCapsule, liquid filledOral120 mgCapsule, liquid filledOral12000000 mgCapsule, liquid filledOral60 mgCapsuleOral60.000 mgCapsuleOral240 mgCapsuleOral120 mg/1Capsule, gelatin coatedOral120 mgCapsule, coatedOral50 %Tablet, solubleOral120 mgCapsuleOral120 mgPricesUnit descriptionCostUnitXenical 120 mg capsule4.44USD capsuleAlli 60 mg capsule0.67USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. PatentsPatent NumberPediatric ExtensionApprovedExpires (estimated)RegionUS4598089No1986-07-012009-12-18CA2383036No2006-01-102020-09-11CA2258095No2000-02-222018-01-24US6004996Yes1999-12-212018-07-06StateSolidExperimental PropertiesPropertyValueSourcemelting point (°C)40-50https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223334/boiling point (°C)616https://www.chemicalbook.com/ChemicalProductProperty_US_CB2431985.aspxlogP4.4https://www.rochecanada.com/PMs/Xenical/Xenical_PM_E.pdfpKa15https://www.chemicalbook.com/ChemicalProductProperty_US_CB2431985.aspxPredicted PropertiesPropertyValueSourceWater Solubility9.19e-05 mg/mLALOGPSlogP7.61ALOGPSlogP8.11ChemaxonlogS-6.7ALOGPSpKa (Strongest Acidic)12.74ChemaxonpKa (Strongest Basic)-1.4ChemaxonPhysiological Charge0ChemaxonHydrogen Acceptor Count3ChemaxonHydrogen Donor Count1ChemaxonPolar Surface Area81.7 Å2ChemaxonRotatable Bond Count23ChemaxonRefractivity139.94 m3·mol-1ChemaxonPolarizability60.88 Å3ChemaxonNumber of Rings1ChemaxonBioavailability0ChemaxonRule of FiveNoChemaxonGhose FilterNoChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.9728Blood Brain Barrier+0.5923Caco-2 permeable-0.5611P-glycoprotein substrateSubstrate0.5411P-glycoprotein inhibitor IInhibitor0.6242P-glycoprotein inhibitor IIInhibitor0.5301Renal organic cation transporterNon-inhibitor0.9097CYP450 2C9 substrateNon-substrate0.854CYP450 2D6 substrateNon-substrate0.826CYP450 3A4 substrateSubstrate0.5867CYP450 1A2 substrateNon-inhibitor0.8458CYP450 2C9 inhibitorNon-inhibitor0.8305CYP450 2D6 inhibitorNon-inhibitor0.8869CYP450 2C19 inhibitorNon-inhibitor0.7315CYP450 3A4 inhibitorNon-inhibitor0.8308CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.907Ames testNon AMES toxic0.7333CarcinogenicityNon-carcinogens0.8628BiodegradationNot ready biodegradable0.7808Rat acute toxicity2.3363 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.9671hERG inhibition (predictor II)Non-inhibitor0.9395 ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) Mass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-03di-2902200000-dfdc46fddbbd1d2170e0LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-001i-0000190000-0f2b7ec7f6bc7f95ba46LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-001i-0000390000-65e16678dbfdcc1c64fdLC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-00di-0001190000-27c5d161a5754e1434f4LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-00di-0001190000-27c5d161a5754e1434f4LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0pb9-0971000000-b771a74c99af15873a47LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0pb9-0971000000-b771a74c99af15873a47Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-2029700000-e18d2d31cb608f8f5a3cPredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0296-1902600000-1a4e364ce3ccfa4484abPredicted
Add Comment